Experimental Neurology 299 (2018) 326–333

Contents lists available at ScienceDirect

Experimental Neurology

journal homepage: www.elsevier.com/locate/yexnr

Review Article
Anti-VEGF treatment improves neurological function in tumors of the
nervous system
Na Zhanga,1,2, Jie Chena,1,3, Gino B. Ferraroa, Limeng Wua, Meenal Dattaa,b, Rakesh K. Jaina,
Scott R. Plotkinc, Anat Stemmer-Rachamimovd,⁎, Lei Xua,⁎⁎

T

a Edwin Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
b Department of Chemical and Biological Engineering, Tufts University, Medford, MA 02155, USA
c Department of Neurology and Cancer Center, Massachusetts General Hospital, USA
d Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

A R T I C L E I N F O

A B S T R A C T

Keywords:
Anti-VEGF treatment
Neurological function
Schwannoma

Research of various diseases of the nervous system has shown that VEGF has direct neuroprotective eﬀects in the
central and peripheral nervous systems, and indirect eﬀects on improving neuronal vessel perfusion which leads
to nerve protection. In the tumors of the nervous system, VEGF plays a critical role in tumor angiogenesis and
tumor progression. The eﬀect of anti-VEGF treatment on nerve protection and function has been recently re-
ported - by normalizing the tumor vasculature, anti-VEGF treatment is able to relieve nerve edema and deliver
oxygen more eﬃciently into the nerve, thus reducing nerve damage and improving nerve function. This review
aims to summarize the divergent roles of VEGF in diseases of the nervous system and the recent ﬁndings of anti-
VEGF therapy in nerve damage/regeneration and function in tumors, speciﬁcally, in Neuroﬁbromatosis type 2
associated schwannomas.

1. Introduction

Vascular endothelial growth factor (VEGF) is a multifunctional cy-
tokine, originally discovered as a tumor-secreted protein that promotes
vascular permeability (Dvorak et al., 1999). VEGF promotes angio-
genesis by inducing migration and proliferation of endothelial cells
(Carmeliet and Jain, 2000; Ferrara, 1999). It is expressed in virtually all
tumor types, and is correlated with angiogenesis, tumor growth, inva-
sion and metastasis (Carmeliet and Jain, 2000). The critical role of
VEGF in angiogenesis and tumor growth has been proven mechan-
istically by the targeted deletion of the Vegfa gene (Grunstein et al.,
1999; Tsuzuki et al., 2000), by blocking antibodies (Yuan et al., 1996)
and by introduction of antisense VEGF constructs into neoplastic cells
(Oku et al., 1998; Xu et al., 2002).

A number of studies have examined the eﬀects of VEGF in the
nervous system (Lambrechts and Carmeliet, 2006; van Bruggen et al.,
1999; Zhang et al., 2000). During embryonic development, VEGF is
expressed in the ventricular zone, and the VEGF receptors are expressed
in endothelial cells of the perineural capillary plexus and capillary

sprouts, inﬁltrating into the neuroectoderm (Breier et al., 1995). In the
adult brain, VEGF, as well as its receptors, VEGF-R1, -R2 and neuro-
pilin-1 (NRP-1), are expressed in a region-speciﬁc manner in glial cells
(Acker et al., 2001; Barouk et al., 2011; Bengoetxea et al., 2008; Licht
et al., 2010; Licht et al., 2011), neurons (Li et al., 2009) and Purkinje
cells (Maharaj et al., 2006; Ruiz de Almodovar et al., 2010). A great
number of reports have shown that VEGF family members exert ver-
satile eﬀects in the nervous system - stimulating neural cell prolifera-
tion, migration, diﬀerentiation and survival during development and in
the adult (Calvo et al., 2011; Falk et al., 2011; Jin et al., 2002; Le Bras
et al., 2006; Licht et al., 2010; Licht et al., 2011; Louissaint et al., 2002;
Palmer et al., 2000; Ruiz de Almodovar et al., 2010; Schanzer et al.,
2004; Sondell et al., 1999; Sun et al., 2006; Wittko et al., 2009). In
recent years, numerous studies have examined the neurotrophic and
neuroprotective roles of VEGF in disease of the nervous system, such as
neurodegenerative disorders (Parkinson's disease and amyotrophic lat-
eral sclerosis (ALS)), ischemic brain injury (e.g., stroke), peripheral
nerve injury, and retinal diseases (Carmeliet, 2003; Ferrara et al., 2003;
Raab and Plate, 2007; Ruiz de Almodovar et al., 2009) (Table 1).

⁎ Correspondence to: A. Stemmer-Rachamimov, Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
⁎⁎ Correspondence to: L. Xu, Department of Radiation Oncology, Cox-7, Massachusetts General Hospital, Boston, MA 02114, USA.
E-mail addresses: astemmerrachamimov@mgh.harvard.edu (A. Stemmer-Rachamimov), lei@steele.mgh.harvard.edu (L. Xu).

1 N.Z. and J.C. contributed equally to this work.
2 Present address: Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing 100730, China.
3 Present address: Department of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.

https://doi.org/10.1016/j.expneurol.2017.09.008
Received 5 February 2017; Received in revised form 5 July 2017; Accepted 10 September 2017
Available online 11 September 2017
0014-4886/ © 2017 Published by Elsevier Inc.

N. Zhang et al.

Experimental Neurology 299 (2018) 326–333

)
4
0
0
2

,
.
l
a

t
e

h
c
s
o
B

n
e
D
n
a
V
(

h
t
a
e
d
m
o
r
f

n
o
r
u
e
n

r
o
t
o
m
c
i
m
e
h
c
s
i

s
t
c
e
t
o
r
p

F
G
E
V

)
3
0
0
2

,
.
l
a

t
e

s
t
h
c
e
r
b
m
a
L
(

n
o
r
u
e
n
r
o
t
o
m
e
r
e
v
e
s
o
t

s
d
a
e
l
n
o
i
t
a
t
u
m
e
n
e
g

r
o
t
o
m
c
i
m
e
h
c
s
i

t
s
n
i
a
g
a

e
c
i
m
d
e
t
c
e
t
o
r
p

a
f
g
e
V

h
t
a
e
d

n
o
r
u
e
n

2
R
-
F
G
E
V
e
h
t

a
f
g
e
V

h
g
u
o
(cid:129)
r
h
t

n
o
i
t
a
r
e
n
e
g
e
d

(cid:129)

F
G
E
V

f
o

n
o
i
t
a
r
t
s
i
n
i
m
d
a

l
a
e
n
o
t
i
r
e
p
a
r
t
n
I

s
n
o
r
u
e
n

r
o
t
o
m

f
o

s
s
o
l

t
s
n
i
a
g
a

s
t
c
e
t
o
r
p

r
o
t
o
m
o
t

e
s
o
p
s
i
d
e
r
p

F
G
E
V
d
e
c
u
d
e
R

e
c
i
m
d
n
a

n
a
m
u
h

n
i

s
s
o
l

n
o
r
u
e
n

r
o
t
o
m

f
o

l
a
v
i
v
r
u
s

s
e
c
n
a
h
n
e

F
G
E
V

s
n
o
r
u
e
n

e
v
i
s
s
e
r
g
o
r
p

o
t

s
d
a
e
l

l
e
v
e
l

F
G
E
V
w
o
L

s
s
e
r
t
s

r
e
t
f
a

s
r
e
d
r
o
s
i
d

e
v
i
t
a
r
e
n
e
g
e
d
o
r
u
e
N

∂
/
∂
f
g
e
V

:

n
o
i
t
a
t
u
m
c
i
t
e
n
e
G

n
o
i
t
c
n
u
f

∂
/
∂
f
g
e
V

:

n
o
i
t
a
t
u
m
c
i
t
e
n
e
G

f
o

n
o
r
u
e
n

f
o

n
o
r
u
e
n

d
r
o
c

d
r
o
c

r
o
t
o
M

l
a
n
i
p
s

r
o
t
o
M

l
a
n
i
p
s

a
i
m
e
h
c
s
i

d
r
o
c

l
a
n
i
p
s

e
l
p
m
a
s

d
o
o
l
b

n
a
m
u
H

e
s
u
o
M
(cid:129)

l
e
d
o
m

(cid:129)

e
r
u
t
l
u
c

n
o
r
u
e
n

t
a
r

d
n
a

e
s
u
o
M

g
n
a
h
Z

;

8
9
9
1

,
.
l
a

t
e

r
y
m
n
n
e
L
(

d
n
a

n
o
i
t
a
m
r
o
f

y
r
a
l
l
i
p
a
c

s
e
c
u
d
n
i

t
n
e
m
t
a
e
r
t

F
G
E
V

s
e
c
n
a
h
n
e

t
n
e
m
t
a
e
r
t

F
G
E
V

t
n
a
n
i
b
m
o
c
e
R

)
0
0
0
2

,
.
l
a

t
e

n
i

n
o
i
s
u
f
r
e
p

a
m
s
a
l
p

r
a
l
u
c
s
a
v
o
r
c
i
m

l
a
r
b
e
r
e
c

s
e
s
a
e
r
c
n
i

l
a
c
i
g
o
l
o
r
u
e
n

s
e
v
o
r
p
m

i

d
n
a

s
i
s
e
n
e
g
o
i
g
n
a

y
r
o
s
n
e
s

d
n
a

r
o
t
o
M

t
s
e
t

n
o
i
t
c
n
u
f

S
N
C

c
i
l
o
b
m
e

l
a
r
b
e
r
e
c

l
a
c
o
f

t
a
R

l
e
d
o
m
a
i
m
e
h
c
s
i

y
t
i
l
i
b
a
e
m
r
e
p

y
r
u
j
n
i

d
n
a

a
m
e
d
e

)
9
9
9
1

,
.
l
a

t
e

n
e
g
g
u
r
B

n
a
v
(

d
n
a

a
m
e
d
e

l
e
s
s
e
v

s
e
c
u
d
e
r

t
s
i
n
o
g
a
t
n
a

F
G
E
V

n
i
a
r
b

s
e
c
u
d
e
r

F
G
E
V

f
o

t
s
i
n
o
g
a
t
n
A

s
i
s
y
l
a
n
a

n
o
i
s
s
e
r
p
x
E

S
N
C

l
e
d
o
m
a
i
m
e
h
c
s
i

n
i
a
r
b

e
s
u
o
M

)
0
0
0
2

,
.
l
a

t
e

n
i
J
(

,

2
R
-
F
G
E
V

a
i
v

s
t
c
e
ﬀ
e

e
v
i
t
c
e
t
o
r
p
o
r
u
e
n

s
e
t
a
i
d
e
m
F
G
E
V

l
a
p
m
a
c
o
p
p
i
h
f
o
h
t
a
e
d

l
l
e
c

s
e
c
u
d
e
r

F
G
E
V

x
e
t
r
o
c

e
h
t

f
o

a
r
b
m
u
n
e
p

e
h
t

y
r
e
v
o
c
e
r

g
n
i
l
a
n
g
i
s

t
k
A
/
K
-
3
I
P

s
n
o
r
u
e
n

e
s
o
c
u
l
g

d
n
a

a
i
x
o
p
y
H

n
i

e
u
c
s
e
r

n
o
i
t
a
v
i
r
p
e
d

y
d
u
t
s

o
r
t
i
v

n
o
r
u
e
n

l
a
p
m
a
c
o
p
p
i
H

e
n
i
l

l
l
e
c

n
o
r
u
e
n

e
s
u
o
M

e
s
u
o
m
h
t
o
b
n
i

s
l
e
s
s
e
v

l
a
r
b
e
r
e
c
d
n
a

s
e
t
y
c
o
r
t
s
a

e
v
i
t
c
a
e
r

c
i
x
o
p
y
h

c
i
n
o
r
h
c

d
n
a

c
i
m
e
h
c
s
i

f
o

x
e
t
r
o
c

e
u
s
s
i
t

n
i
a
r
b

n
a
m
u
h

d
n
a

l
a
r
b
e
r
e
c

t
n
e
d
n
e
p
e
d
-
5
6
1
f
g
e
V

t
n
e
i
c

ﬃ
u
s
n
i

d
n
a

n
o
i
s
u
f
r
e
p

r
a
l
u
c
s
a
v

n
o
i
t
c
e
t
o
r
p
o
r
u
e
n

y
h
p
o
r
t
a

)
8
9
9
1

,
.
l
a

t
e

a
i
r
a
l
a
K
(

f
o

s
r
e
t
s
u
l
c

n
i

y
t
i
v
i
t
c
a
e
r
o
n
u
m
m

i

F
G
E
V

d
e
c
n
a
h
n
E

l
a
r
b
e
r
e
c

n
i

n
o
i
s
s
e
r
p
x
e

F
G
E
V

d
e
s
a
e
r
c
n
I

s
i
s
y
l
a
n
a

n
o
i
s
s
e
r
p
x
E

x
e
t
r
o
c

l
a
r
b
e
r
e
C

l
e
d
o
m
a
i
m
e
h
c
s
i

l
a
r
b
e
r
e
c

t
a
R

)
1
0
0
2

,
.
l
a

t
e

e
s
y
u
h
t
s
o
O
(

e
r
u
t
a
l
u
c
s
a
v

l
a
m
r
o
n
b
a

d
n
a

n
o
i
s
s
e
r
p
x
e

F
G
E
V

d
e
c
u
d
e
R

l
a
r
u
e
n

d
e
c
u
d
e
r

o
t

d
a
e
l

e
c
i
m
c
i
n
e
g
s
n
a
r
t

∂
/
∂
f
g
e
V

n
i

e
l
c
s
u
m
d
n
a

n
o
i
t
a
r
e
n
e
g
e
d

n
o
r
u
e
n

r
o
t
o
m

∂
/
∂
f
g
e
V

:

n
o
i
t
a
t
u
m
c
i
t
e
n
e
G

f
o

n
o
r
u
e
n

d
r
o
c

r
o
t
o
M

l
a
n
i
p
s

l
e
d
o
m
e
s
u
o
M

)
1
0
0
2

,
.
l
a

t
e

n
i
J
(

r
e
d
n
u

3
-
e
s
a
p
s
a
c

f
o

n
o
i
t
a
v
i
t
c
a

e
h
t

s
t
i
b
i
h
n
i

F
G
E
V

r
o
t
c
a
f

e
v
i
t
c
e
t
o
r
p
o
r
u
e
n

n
a

s
a

s
t
c
a

F
G
E
V

o
r
t
i
v

n
i

e
u
c
s
e
r

a
i
x
o
p
y
H

n
o
r
u
e
n

l
a
c
i
t
r
o
C

e
r
u
t
l
u
c

n
o
r
u
e
n

e
s
u
o
M

a
i
m
e
h
c
s
i

l
a
r
b
e
r
e
C

s
e
c
n
e
r
e
f
e
R

s

m

s
i
n
a
h
c
e
M

s
g
n
i
d
n
i
F

F
G
E
V

s
s
e
s
s
a

o
t

d
o
h
t
e
M

n
o
r
u
e
n
/
e
v
r
e
N

l
e
d
o
M

e
s
a
e
s
i
D

.

m
e
t
s
y
s

s
u
o
v
r
e
n

e
h
t

f
o

s
e
s
a
e
s
i
d

n
i

g
n
i
l
a
n
g
i
s

F
G
E
V

1

e
l
b
a
T

y
r
u
j
n
i

n
i
a
r
b

c
i
m
e
h
c
s
I

e
k
o
r
t
S

e
k
o
r
t
S

e
k
o
r
t
S

S
L
A

S
L
A

S
L
A

D
A

e
v
r
e
n

l
a
r
e
h
p
i
r
e
p

e
r
u
t
l
u
c

n
o
r
u
e
n

a
i
l
g
n
a
g

l
a
n
i
m
e
g
i
r
t

e
r
u
t
l
u
c

n
o
r
u
e
n

e
r
u
t
l
u
c

l
e
d
o
m
y
r
u
j
n
i

l
e
d
o
m
e
g
a
m
a
d

l
a
e
n
r
o
c

l
e
d
o
m
n
e
o
s
i
u
t
o
c
e
M
s
n
(cid:129)
a
r
t

c
i
t
a
i
c
s

t
a
r
/
e
s
u
o
M

e
s
u
o
M
(cid:129)

t
n
a
l
p
x
e

e
s
u
o
M
(cid:129)

e
v
r
e
n

s
u
o
n
r
e
v
a
c

e
s
u
o
M

l
e
d
o
m
y
m
o
t
o
r
u
e
n

e
r
u
t
l
u
c
G
P
M

t
a
R

l
e
d
o
m
y
r
u
j
n
i

e
e
s
s
u
u
o
o
M
M
(cid:129)
(cid:129)

e
e
s
s
u
u
o
o
M
M
(cid:129)
(cid:129)

y
r
u
j
n
I

y
r
u
j
n
I

y
r
u
j
n
I

y
r
u
j
n
I

y
r
u
j
n
I

y
r
u
j
n
I

327

;

3
1
0
2

)
1
1
0
2

,
.
l
a

,
.
l
a

t
e

t
e

i
d
a
m
m
a
h
o
M

(

s
e
p
o
L

a
r
i
e
r
e
P

c
i
h
p
o
r
t
o
r
u
e
n

,
c
i
n
e
g
o
i
g
n
a

d
e
c
n
a
h
n
e

f
o

n
o
i
t
a
n
i
b
m
o
C

s
t
c
e
ﬀ
e

e
v
i
t
c
e
t
o
r
p
o
r
u
e
n

d
n
a

f
o

h
t
w
o
r
g

e
h
t

s
e
c
n
a
h
n
e

F
G
E
V

s
r
e
b
ﬁ

e
v
r
e
n

g
n
i
t
a
r
e
n
e
g
e
r

t
s
e
t

t
s
e
t

l
a
r
o
i
v
a
h
e
B

l
a
n
o
i
t
c
n
u
F

1
-
P
R
N
d
n
a

,

2
R
-
F
G
E
V

s
n
o
r
u
e
n

(cid:129)

(cid:129)

)
8
0
0
2

,
.
l
a

t
e

u
Y
(

n
o
i
t
a
r
e
n
e
g
e
r

d
n
a

h
t
w
o
r
g

n
o
r
u
e
n

s
e
c
u
d
e
r

F
G
E
V

-
i
t
n
A

r
i
a
p
e
r

e
h
t

s
t
i
b
i
h
n
i

t
n
e
m
t
a
e
r
t

F
G
E
V

-
i
t
n
A

s
i
s
y
l
a
n
a

s
e
v
r
e
n

l
a
e
n
r
o
c

f
o

n
o
i
s
s
e
r
p
x
E

e
v
r
e
n

l
a
e
n
r
o
C

e
v
r
e
n

e
v
r
e
n

c
i
t
a
i
c
S

e
v
r
e
n

)
4
1
0
2

,
.
l
a

t
e

l
i
u
q
i
a
u
G
(

h
c
t
o
N
d
n
a

K
3
I
P

a
i
v

B
-
F
G
E
V

f
o

t
c
e
ﬀ
e

c
i
h
p
o
r
t
o
r
u
e
N

n
o
i
t
a
r
e
n
e
g
e
r

e
v
r
e
n

s
e
t
a
l
u
m

i
t
s

B
-
F
G
E
V

g
n
i
l
a
n
g
i
s

n
o
i
t
a
s
n
e
s

e
u
s
s
i
t

f
o

y
r
e
v
o
c
e
r

d
n
a

n
o
i
t
i
d
n
o
c

c
i
x
o
p
y
h

a
i
m
e
h
c
s
i

l
a
r
b
e
r
e
c

n
i

y
r
u
j
n
i

e
v
r
e
n

y
r
e
h
p
i
r
e
P

:
t
u
o
-
k
c
o
n
k

c
i
t
e
n
e
G

/

−
−
b
-
f
g
e
V

n
o
r
u
e
n

o
r
t
i
v

n
I

h
t
w
o
r
g

(cid:129)

(cid:129)

y
d
u
t
s

)
3
1
0
2

,
.
l
a

t
e

n
a
P
(

,

1
R
-
F
G
E
V

g
n
i
t
a
v
i
t
c
a

a
i
v

F
G
E
V

f
o

t
c
e
ﬀ
e

c
i
h
p
o
r
t
o
r
u
e
N

l
a
n
i
m
e
g
i
r
t

f
o

h
t
w
o
r
g

s
e
t
a
i
d
e
m
F
G
E
V

t
s
e
t

l
a
n
o
i
t
c
n
u
f

y
r
o
s
n
e
S

e
v
r
e
n

l
a
e
n
r
o
C

e
v
r
e
n

l
a
e
n
r
o
C

e
v
r
e
n

l
a
r
e
h
p
i
r
e
p

e
r
u
t
l
u
c

n
o
r
u
e
n

)
0
0
0
2

,
.
l
a

t
e

r
e
g
r
e
b
z
t
a
r
h
c
S
(

n
o
i
s
u
f
r
e
p

l
e
s
s
e
v

s
e
c
n
a
h
n
e

F
G
E
V

r
e
f
s
n
a
r
t

e
n
e
g

F
G
E
V

r
a
l
u
c
s
u
m
a
r
t
n
I

n
o
i
t
c
u
d
n
o
c

)
4
1
0
2

,
.
l
a

t
e

n
a
m

s
t
r
a
v
h
S
(

F
N
D
G
d
n
a

F
G
N

f
o

n
o
i
s
s
e
r
p
x
e

s
e
c
u
d
n
i

F
G
E
V

n
i

s
t
l
u
s
e
r

n
o
i
t
a
t
n
e
m
e
l
p
p
u
s

F
G
E
V

)
4
0
0
2

,
e
u
L

d
n
a

)
3
0
0
2

,
.
l
a

t
e

n
i
L
(

n
i
L
(

S
O
N
n

g
n
i
t
a
l
u
g
e
r
p
u

a
i
v

h
t
w
o
r
g

n
o
x
a

s
e
t
a
t
i
l
i
c
a
f

s
n
o
r
u
e
n

n
i

H
T

d
n
a

S
O
N
s
e
c
u
d
n
i

F
G
E
V

F
G
E
V

n
o
i
s
s
e
r
p
x
e

h
t
w
o
r
g
t
u
o

r
e
b
ﬁ
G
P
M

s
e
t
o
m
o
r
p

F
G
E
V

h
t
w
o
r
g
t
u
o

F
G
E
V

f
o

n
o
i
t
c
e
j
n
i

s
u
o
n
r
e
v
a
c
a
r
t
n
I

e
l
i
t
c
e
r
e

f
o

y
r
e
v
o
c
e
r

e
h
t

s
e
t
a
t
i
l
i
c
a
f

h
t
w
o
r
g
t
u
o

n
o
i
t
c
n
u
f

e
t
i
r
u
e
N

e
l
i
t
c
e
r
E

e
t
i
r
u
(cid:129)
e
N

(cid:129)

n
o
i
t
c
n
u
f

n
o
i
t
a
u
l
a
v
e

e
v
r
e
n

s
u
o
n
r
e
v
a
C

e
v
r
e
n

c
i
v
l
e
P

s
e
s
n
o
p
s
e
r

c
i
n
e
g
o
r
u
e
n

d
n
a

c
i
n
e
g
o
i
g
n
a

n
o
i
t
a
u
l
a
v
e

n
o
i
t
c
n
u
f

e
v
r
e
n

s
r
e
v
o
c
e
r

l
l
e
c

n
n
a
w
h
c
S

e
t
a
l
p
-
d
n
e

r
o
t
o
M

n
o
i
t
a
r
g
i
m

e
v
r
e
N

n
o
i
t
a
v
r
e
n
(cid:129)
n
i

(cid:129)

e
l
c
s
u
m
d
i
o
t
s
a
m
o
n
r
e
t
S

y
r
u
j
n
i

e
v
r
e
n

l
a
r
e
h
p
i
r
e
p

e
s
u
o
M

y
r
u
j
n
i

c
i
m
e
h
c
s
I

e
v
r
e
n

l
e
d
o
m

e
v
r
e
n

l
a
e
n
o
r
e
P

a
i
m
e
h
c
s
i

b
m

i
l

d
n
i
h

t
i
b
b
a
R

y
r
u
j
n
i

a
i
m
e
h
c
s
I

l
e
d
o
m

)
e
g
a
p

t
x
e
n

n
o

d
e
u
n
i
t
n
o
c
(

)
9
9
9
1

,
.
l
a

t
e

l
l
e
d
n
o
S
(

s
l
l
e
c

n
n
a
w
h
c
S

,
s
n
o
r
u
e
n

f
o

n
o
i
t
a
r
e
f
i
l
o
r
p

s
l
e
d
o
m
e
r
u
t
l
u
c

y
r
u
j
n
i

d
n
a

l
a
v
i
v
r
u
s

s
e
s
a
e
r
c
n
i

F
G
E
V

h
t
w
o
r
g
t
u
o

e
t
i
r
u
e
N

G
R
D

,

G
C
S

t
n
a
l
p
x
e
G
R
D
d
n
a
G
C
S

e
s
u
o
M

e
v
r
e
n

l
a
r
e
h
p
i
r
e
P

N. Zhang et al.

Experimental Neurology 299 (2018) 326–333

ﬀ
e
o
h
r
e
V

;

0
1
0
2

,
.
l
a
t
e
e
e
G
c
M

(

r
o
m
u
t

n
i
a
r
b

s
e
z
i
l
a
m
r
o
n

y
l
t
n
e
i
s
n
a
r
t

e
d
a
k
c
o
l
b

2
R
F
G
E
V

,
.
l
a

t
e

r
e
l
k
n
i
W

;

9
0
0
2

,
.
l
a

t
e

)
4
0
0
2

n
o
i
t
a
v
i
t
c
a

P
M
M
d
n
a

1
g
n
A

f
o

n
o
i
t
a
l
u
g
e
r
p
u

a
i
v

s
l
e
s
s
e
v

1
-
P
R
N

f
o

n
o
i
t
a
z
i
l
a
m
r
o
n
“

e
h
t

g
n
i
r
u
d

d
e
r
e
t
s
i
n
i
m
d
a

F
G
E
V

-
i
t
n
a

y
b

d
e
c
u
d
n
i

”
w
o
d
n
i
w

)
9
0
0
2

,
.
l
a

t
e

e
r
u
t
a
l
u
c
s
a
v

r
o
m
u
t

d
n
a

s
e
t
a
r

e
s
n
o
p
s
e
r

c
i
h
p
a
r
g
o
i
d
a
r

l
s
i
e
r
K

;

9
0
0
2

,
.
l
a

t
e
n
a
m
d
e
i
r
F
(

n
i
a
r
b

f
o

n
o
i
t
a
z
i
l
a
m
r
o
n

s
e
c
u
d
n
i

t
n
e
m
t
a
e
r
t

F
G
E
V

-
i
t
n
A

t
n
a
c
ﬁ
i
n
g
i
s

o
t

s
d
a
e
l

t
n
e
m
t
a
e
r
t

F
G
E
V

-
i
t
n
A

l
i
a
r
t

l
a
c
i
n
i
l

C

s
t
n
e
i
t
a
p
M
B
G
r

t
n
e
m
t
a
e
r
t

t
r
e
b
l
i

G

;

4
1
0
2

,
.
l
a

t
e

t
o
n
i
h
C
(

n
i
a
r
b

f
o

n
o
i
t
a
z
i
l
a
m
r
o
n

s
e
c
u
d
n
i

t
n
e
m
t
a
e
r
t

F
G
E
V

-
i
t
n
A

h
g
r
u
b
n
e
d
e
r
V

;

4
1
0
2

)
7
0
0
2

,
.
l
a

,
.
l
a

t
e

t
e

e
r
u
t
a
l
u
c
s
a
v

r
o
m
u
t

h
t
i

w
d
e
n
i
b
m
o
c

t
n
e
m
t
a
e
r
t

F
G
E
V

-
i
t
n
A

S
F
P

s
e
v
o
r
p
m

i

Z
M
T

d
n
a

y
p
a
r
e
h
t
o
i
d
a
r

S
O
n
a
i
d
e
m
n
i

t
n
e
m
e
v
o
r
p
m

i

o
N

S
F
P

d
e
v
o
r
p
m

i

l
i
a
r
t

l
a
c
i
n
i
l

C

s
t
n
e
i
t
a
p
M
B
G
n

)
8
2
0
3
1
6
0
0
T
C
N

,

4
9
0
3
9
3
0
0
T
C
N

s
l
a
i
r
t

l
a
c
i
n
i
l
c

I
I
I

e
s
a
h
P

s
l
a
i
r
t

l
a
c
i
n
i
l
c

I
I

e
s
a
h
P

,

3
6
1
5
4
3
0
0
T
C
N
(

,

1
4
7
4
8
8
0
0
T
C
N
(

)
6
2
8
3
4
9
0
0
T
C
N

l
e
d
o
m

n
e
h
w
e
v
i
t
c
e
ﬀ
e

t
s
o
m

s
i

n
o
i
t
a
i
d
a
R

t
n
e
m
t
a
e
r
t

R
F
G
E
V

-
i
t
n
A

n
i
a
r
B

t
f
a
r
g
o
n
e
x

c
i
p
o
t
o
h
t
r
o

e
s
u
o
M

)
1
1
0
2

,
.
l
a

t
e

n
e
t
r
a
g
m
u
a
B

t
c
e
ﬀ
e

r
o
m
u
t
-
i
t
n
a
t
c
e
r
i
d
s
a
h
b
a
m
u
z
i
c
a
v
e
b
f
o
e
s
o
d
h
g
i
H

a
m
e
d
e

g
n
i
l
l
o
r
t
n
o
c

y
b

e
c
i
m
e
h
t

f
o

n
o
v
(

)
9
0
0
2

,
.
l
a

t
e

n
u
o
m
a
K
(

s
l
e
s
s
e
v

d
o
o
l
b

r
o
m
u
t

s
e
z
i
l
a
m
r
o
n

t
n
e
m
t
a
e
r
t

F
G
E
V

-
i
t
n
A

l
a
v
i
v
r
u
s

s
e
v
o
r
p
m

i

t
n
e
m
t
a
e
r
t

F
G
E
V

-
i
t
n
A

t
n
e
m
t
a
e
r
t

R
F
G
E
V

-
i
t
n
A

n
i
a
r
B

w
o
d
n
i
w

l
a
i
n
a
r
c

l
a
i
r
t

l
a
c
i
n
i
l
c

I
I

m
e
t
s
y
s

s
u
o
v
r
e
n

l
a
r
t
n
e
c

e
h
t

f
o

s
r
o
m
u
T

t
n
a
l
p
x
e

l
a
n
i
t
e
r

,
.
l
a

t
e

n
o
S

;

6
1
0
2

,
.
l
a

t
e

e
e
L
(

-
Z
M
T

e
c
n
a
h
n
e

n
a
c

t
n
e
m
t
a
e
r
t

F
G
E
V

-
i
t
n
a

d
e
n
i
b
m
o
C

)
6
0
0
2

n
o
i
t
a
l
u
g
e
r
-
n
w
o
d

c
ﬁ
i
c
e
p
s

h
g
u
o
r
h
t

s
i
s
o
t
p
o
p
a

d
e
c
u
d
n
i

h
t
w
o
r
g

r
o
m
u
t

s
t
i
b
i
h
n
i

t
n
e
m
t
a
e
r
t

Z
M
T

d
n
a

F
G
E
V

-
i
t
n
a

d
e
n
i
b
m
o
C

t
n
e
m
t
a
e
r
t

R
F
G
E
V

-
i
t
n
A

n
i
a
r
B

l
e
d
o
m

t
f
a
r
g
o
n
e
x

e
s
u
o
M
(cid:129)

e
s
a
h
P

l
e
d
o
m
(cid:129)

c
i
p
o
t
o
h
t
r
O

f
o
n
o
i
t
a
r
e
f
i
l
o
r
p
s
e
s
a
e
r
c
n
i
d
n
a

l
a
v
i
v
r
u
s

s
e
v
o
r
p
m

i
F
G
E
V

K
P
A
M
e
h
t

d
n
a

2
R
-
F
G
E
V

h
g
u
o
r
h
t

s
l
l
e
c

n
n
a
w
h
c
S

y
a
w
h
t
a
p

)
3
1
0
2

,
.
l
a

t
e

n
o
t
x
o
F
(

d
n
a

2
R
-
F
G
E
V
a
i
v

F
G
E
V

f
o

t
c
e
ﬀ
e

e
v
i
t
c
e
t
o
r
p
o
r
u
e
N

s
l
l
e
c

n
o
i
l
g
n
a
g

l
a
n
i
t
e
r

s
e
t
o
m
o
r
p
A
-
F
G
E
V

h
t
w
o
r
g
t
u
o

e
t
i
r
u
e
N

s
l
l
e
c

n
o
i
l
g
n
a
g

l
a
n
i
t
e
R

l
l
e
c

n
o
i
l
g
n
a
g

l
a
n
i
t
e
r

t
a
R

e
s
a
e
s
i
d

l
a
n
i
t
e
R

y
a
w
h
t
a
p

t
k
A
/
K
3
I
P

l
a
v
i
v
r
u
s

a
m
o
c
u
a
l
g

e
v
i
s
n
e
t
r
e
p
y
h

l
a
t
n
e
m

i
r
e
p
x
e

t
a
R

l
e
d
o
m
e
r
u
t
l
u
c

l
e
d
o
m

(cid:129)

(cid:129)

a
m
o
c
u
a
l
G

s
e
c
n
e
r
e
f
e
R

s

m

s
i
n
a
h
c
e
M

s
g
n
i
d
n
i
F

F
G
E
V

s
s
e
s
s
a

o
t

d
o
h
t
e
M

n
o
r
u
e
n
/
e
v
r
e
N

l
e
d
o
M

e
s
a
e
s
i
D

n
o
i
t
c
n
u
f

)
d
e
u
n
i
t
n
o
c
(

1

e
l
b
a
T

)
2
0
0
2

,
.
l
a

t
e

t
r
e
ﬀ
e
M

-
r
e
k
c
o
B
(

2
R
-
F
G
E
V
a
i
v

h
t
w
o
r
g
t
u
o

l
a
n
o
x
a

s
e
t
a
l
u
m

i
t
s

F
G
E
V

f
o

h
t
w
o
r
g
t
u
o

s
e
t
i
r
u
e
n

s
e
c
u
d
n
i

w
o
ﬂ

d
o
o
l
b

s
e
s
a
e
r
c
n
i

F
G
E
V

F
G
E
V

)
7
0
0
2

,
.
l
a

t
e

a
m

i
j
i
h
s
i
N
(

2
R
-
F
G
E
V

a
i
v

F
G
E
V

f
o

t
c
e
ﬀ
e

e
v
i
t
c
e
t
o
r
p
o
r
u
e
n

t
c
e
r
i
D

l
l
e
c

l
a
n
i
t
e
r

s
e
u
c
e
r

y
l
t
c
e
r
i
d

F
G
E
V

S
O
N

i

a
i
v
w
o
ﬂ

d
o
o
l
b

s
e
s
a
e
r
c
n
i

F
G
E
V

s
i
s
o
t
p
o
p
a

s
t
e
l
e
t
a
l
p

d
n
a

s
l
i
h
p
o
r
t
u
e
n

n
o
i
t
a
r
e
n
e
g
e
r

e
v
r
e
n

s
d
r
a
t
e
r

y
l
l
a
c
o
l

d
n
a

t
n
e
m
t
a
e
r
t

F
G
E
V

-
i
t
n
A

s
s
e
n
k
c
i
h
t

l
a
n
i
t
e
R

n
o
i
t
a
u
l
a
v
e

t
n
e
m
t
a
e
r
t

R
F
G
E
V

-
i
t
n
A

(cid:129)

(cid:129)

)
1
1
0
2

,
.
l
a

t
e

i
L
(

g
n
i
v
l
o
v
n
i

e
s
n
o
p
s
e
r

y
r
o
t
a
m
m
a
ﬂ
n
i

s
e
c
u
d
e
r

F
G
E
V

-
i
t
n
A

y
l
l
a
c
i
m
e
t
s
y
s

d
e
r
e
t
s
i
n
i
m
d
a

F
G
E
V

-
i
t
n
A

t
n
e
m
t
a
e
r
t

F
G
E
V

-
i
t
n
A

e
v
r
e
n

l
a
e
n
r
o
C

l
e
d
o
m
n
o
i
s
a
r
b
a

l
a
e
n
r
o
c

e
s
u
o
M

n
o
i
t
a
m
m
a
ﬂ
n
I

e
v
r
e
n

c
i
t
p
O

n
o
i
s
u
f
r
e
p
e
r
-
a
i
m
e
h
c
s
i

e
s
u
o
M

a
i
m
e
h
c
s
i

l
a
n
i
t
e
R

y
r
u
j
n
i

t
n
a
l
p
x
e

l
a
n
i
t
e
R

l
e
d
o
m

t
n
a
l
p
x
e

l
a
n
i
t
e
r

t
a
R

a
i
m
e
h
c
s
i

l
a
n
i
t
e
R

M
B
G

M
B
G

M
B
G

M
B
G

M
B
G

328

l
a
i
l
e
h
t
o
d
n
e

r
a
l
u
c
s
a
v

,

B
-
F
G
E
V

;

A
r
o
t
c
a
f
h
t
w
o
r
g

l
a
i
l
e
h
t
o
d
n
e

r
a
l
u
c
s
a
v

,

A
-
F
G
E
V

;

2
r
o
t
p
e
c
e
r

F
G
E
V

,

2
R
-
F
G
E
V

;

1
r
o
t
p
e
c
e
r

F
G
E
V

,

1
R
-
F
G
E
V

;
r
o
t
c
a
f
h
t
w
o
r
g

l
a
i
l
e
h
t
o
d
n
e

r
a
l
u
c
s
a
v

,
F
G
E
V

;
r
e
i
r
r
a
b
d
o
o
l
b
n
i
a
r
b

,

B
B
B

;

m
e
t
s
y
s

s
u
o
v
r
e
n
l
a
r
t
n
e
c

,
S
N
C

:
s
n
o
i
t
a
i
v
e
r
b
b
A

l
a
i
l
g

,
F
N
D
G

;
r
o
t
c
a
f
h
t
w
o
r
g

e
v
r
e
n

,
F
G
N

;
e
s
a
h
t
n
y
s

e
d
i
x
o

c
i
r
t
i
n
l
a
n
o
r
u
e
n

,
S
O
N
n

;
e
s
a
h
t
n
y
s

e
d
i
x
o

c
i
r
t
i
n
e
l
b
i
c
u
d
n
i

,
S
O
N

i

;
e
s
a
h
t
n
y
s

e
d
i
x
o

c
i
r
t
i
n

,
S
O
N

;
a
i
l
g
n
a
g

c
i
v
l
e
p
r
o
j
a
m

,

G
P
M

;
e
s
a
n
i
k
-
3

l
o
t
i
s
o
n
i
l
y
d
i
t
a
h
p
s
o
h
p

,

K
3
I
P

;

1
n
i
l
i
p
o
r
u
e
n

,

1
-
P
R
N

;

B
r
o
t
c
a
f
h
t
w
o
r
g

;

1
-
n
i
t
e
i
o
p
o
i
g
n
a

,

1
g
n
A

;
e
d
i
m
o
l
o
z
o
m
e
t

,

Z
M
T

;
a
m
o
t
s
a
l
b
o
i
l
g

,

M
B
G

;
e
s
a
l
y
x
o
r
d
y
h

e
n
i
s
o
r
y
t

,

H
T

;
e
s
a
e
s
i
d

'

s
r
e
m
i
e
h
z
l
A

,

D
A

;
e
s
a
n
i
k

n
i
e
t
o
r
p

d
e
t
a
v
i
t
c
a

n
e
g
o
t
i

m

,

K
P
A
M

;
a
i
l
g
n
a
g

t
o
o
r

l
a
s
r
o
d

,

G
R
D

;
a
i
l
g
n
a
g

l
a
c
i
v
r
e
c

r
o
i
r
e
p
u
s

,

G
C
S

;
r
o
t
c
a
f

c
i
h
p
o
r
t
o
r
u
e
n

d
e
v
i
r
e
d

.

M
B
G
d
e
s
o
n
g
a
i
d

y
l
w
e
n

,

M
B
G
n

;

M
B
G

t
n
e
r
r
u
c
e
r

,

M
B
G
r

,
l
a
v
i
v
r
u
s

l
l
a
r
e
v
o

,
S
O

;
l
a
v
i
v
r
u
s

e
e
r
f
-
n
o
i
s
s
e
r
g
o
r
p

,
S
F
P

;
e
s
a
n
i
e
t
o
r
p
o
l
l
a
t
e
m
x
i
r
t
a
m

,

P
M
M

n
o
i
t
c
n
u
f

l
a
c
i
g
o
l
o
r
u
e
n

s
e
v
o
r
p
m

i

d
n
a

y
h
p
o
r
t
a

e
l
c
s
u
m

s
e
s
a
e
r
c
e
d

,

n
o
i
t
a
r
e
n
e
g
e
r

n
o
i
t
c
n
u
f

l
a
c
i
g
o
l
o
r
u
e
n

s
e
v
o
r
p
m

i

d
n
a

e
v
r
e
n

s
e
s
a
e
r
c
n
i

,
a
m
e
d
e

e
v
r
e
n

d
n
a

r
o
m
u
t

s
e
c
u
d
e
r

,

n
o
i
t
a
i
d
a
r

f
o

e
s
o
d

s
e
s
a
e
r
c
e
d

,

n
o
i
t
i
b
i
h
n
i

)
5
1
0
2

,
.
l
a

t
e

o
a
G
(

,
e
r
u
t
a
l
u
c
s
a
v

r
o
m
u
t

s
e
z
i
l
a
m
r
o
n

t
n
e
m
t
a
e
r
t

F
G
E
V

-
i
t
n
A

r
o
m
u
t

s
e
c
n
a
h
n
e

t
n
e
m
t
a
e
r
t

F
G
E
V

-
i
t
n
A

t
n
e
m
t
a
e
r
t

F
G
E
V

-
i
t
n
A

e
v
r
e
n

c
i
t
a
i
c
S

l
a
i
n
a
r
c
a
r
t
n
I

l
e
d
o
m

(cid:129)

(cid:129)

t
f
a
r
g
o
n
e
x

c
i
p
o
t
o
h
t
r
o

e
s
u
o
M

a
m
o
n
n
a
w
h
c
S

2
F
N

s
a
m
o
n
n
a
w
h
c
S

l
e
d
o
m

N. Zhang et al.

Experimental Neurology 299 (2018) 326–333

However, its role and potential as a therapeutic target in tumors of the
nervous system remain unknown.

2. Role of VEGF in the nervous system

In various disease models, the eﬀect of VEGF on nerves is two fold:
1) a direct neuroprotective eﬀect on neurons (Jin et al., 2001; Jin et al.,
2000; Lambrechts and Carmeliet, 2006); and 2) an indirect angiogenic
eﬀect that provides an “angiogenic niche”, which improves neural
perfusion and favors neuronal progenitor proliferation and diﬀer-
entiation in vivo (Hoke, 2006; Lambrechts and Carmeliet, 2006; Palmer
et al., 2000; Webber and Zochodne, 2010).

The level of VEGF has been demonstrated to be a factor in neuro-
degenerative disorders. ALS is a progressive, adult-onset neurodegen-
erative disease characterized by degeneration and loss of the large
motor neurons in the cerebral cortex, brainstem and spinal cord,
leading to muscle atrophy, paralysis and death (Al-Chalabi et al., 2017).
The clinical symptoms and neuropathological signs of ALS have been
successfully reproduced in a genetic mouse model in which the hypoxia
response element (HRE) of the Vegfa promoter is mutated. The abol-
ishment of hypoxic regulation of VEGF leads to signiﬁcantly reduced
spinal VEGF levels, which results in decreased neural perfusion, with
spinal cord ischemia, and ultimately leads to both motor neuron de-
generation and progressive paralysis (Lambrechts et al., 2003). This
study exhibited that the vascular function of VEGF plays an important
role in the nervous system homeostasis. In other late-onset neurode-
generative diseases including Alzheimer's dementia and Parkinson's
disease, substantial evidence has shown that decreased cerebral perfu-
sion becomes signiﬁcant during aging. The reduced blood supply and
impeded delivery of oxygen and metabolism of glucose leads to a
chronic mismatch between blood ﬂow and neural energy consumption,
which may destabilize neurons and induce neurodegeneration (de la
Torre, 2000; Farkas et al., 2000) (Table 1).

In ischemic brain injury (stroke), expression of VEGF is highly up-
regulated after onset of ischemia (Plate et al., 1999). In a rat middle
cerebral artery occlusion (MCAO) model, administration of
re-
combinant VEGF 24 h after ischemia (via intracerebroventricular route)
demonstrates enhanced cerebral angiogenesis and microvascular per-
fusion, and signiﬁcantly improves neurological recovery and reduces
damaged brain volume (Guaiquil et al., 2014; Sun et al., 2003; Zhang
et al., 2000). In addition to the vascular eﬀects, VEGFR-1 and R2 are
also upregulated in neurons and glial cells, and NRP-1 is also upregu-
lated in neurons and astrocytes surrounding the infarct. Furthermore,
VEGFR-2 has been shown to mediate the neuroprotective eﬀects of
VEGF via PI3-K/Akt signaling (Table 1). These studies suggest that
VEGF may be directly involved in neuroprotection during stroke re-
covery (Jin et al., 2000).

In peripheral nerve injury, VEGF has been identiﬁed as a signaling
factor that facilitates the crosstalk between the neural and vascular
systems. In a sciatic nerve transection model, local application of VEGF
accelerates functional recovery (Mohammadi et al., 2013); furthermore,
it has been shown that administration of VEGF supports and enhances
the growth of regenerating nerve ﬁbers, through a combination of an-
giogenic, neurotrophic and neuroprotective eﬀects (Pereira Lopes et al.,
2011).
Interestingly, VEGF accelerates nerve growth only in re-
generating nerves, which results in more rapid return of sensation and
neurotrophic eﬀects. This eﬀect has been found to require the activa-
tion of multiple VEGF receptors, VEGFR1, VEGFR2, and NRP-1 (Pan
et al., 2013) (Table 1).

The cornea is among one of the most densely innervated tissues of
the human body. In diseases of the eye, recombinant VEGF directly
promotes the growth of nerve processes from trigeminal ganglia ex-
plants in vitro, whereas anti-VEGF antibody (bevacizumab) reduces
cultured axon growth (Yu et al., 2008). In the neuroﬂuorescent thy1-
YFP mouse, it has been found that the trigeminal ganglion expresses
VEGF and its receptors VEGF-R1, VEGF-R2, NRP-1, and NRP-2,

conﬁrming that the trigeminal neurons have the receptors to respond to
VEGF in vivo. Indeed, in a corneal epithelium nerve damage model,
bevacizumab treatment signiﬁcantly inhibits the repair of the nerves.
Consistent with these ﬁndings, studies of ocular vascular diseases using
optical nerve ischemia-reperfusion injury model have found that VEGF
has a direct survival eﬀect on neuronal cells of the retina, independent
of blood ﬂow, and that VEGFR2 activation is suﬃcient to trigger retinal
neuroprotection (Bocker-Meﬀert et al., 2002; Nishijima et al., 2007). In
models of experimental glaucoma, VEGF, via the PI3K/Akt pathway,
also acts directly on retinal ganglion cells (RGCs) to promote survival
(Foxton et al., 2013) (Table 1). In eye disease, the disruption of the
corneal nerves has been shown to signiﬁcantly impair corneal healing;
therefore, these studies suggest a cautious use of the anti-VEGF treat-
ment in disease of the eye.

Taken together, these ﬁndings suggest that VEGF may ameliorate
the adverse clinical outcomes of stroke, peripheral nerve injury and
neurodegenerative disorders. However, approaches utilizing VEGF ad-
ministration have had limited success, likely due to the rapid clearance
of VEGF protein delivered in a solution form. Infusion of VEGF in
clinical trials resulted in elevated VEGF plasma levels during the infu-
sion, but this was followed by a rapid clearance of VEGF once infusions
were discontinued (Eppler et al., 2002). Studies aimed to improve drug
delivery have shown that poly(lactic-co-glycolic) acid (PLGA) micro-
particles as carriers for VEGF helped to preserve the VEGF bioactivity in
a rat myocardial infarction model (Simon-Yarza et al., 2013). However,
more preclinical studies are needed to evaluate the possible therapeutic
eﬀect on improving neurological function and the side eﬀects of
chronical administration of VEGF in these diseases.

3. Eﬀect of anti-VEGF treatment in tumors of the central nervous
system

Compared to the above-mentioned diseases of the nervous system,
the role of VEGF on neurological functions in patients with tumors of
the nervous system remains to be elucidated. Multiple preclinical and
clinical studies have reported potential roles of VEGF on the progres-
sion of malignant brain tumors (Lu-Emerson et al., 2015). In glio-
blastoma (GBM) preclinical models, anti-VEGF treatment enhances the
eﬃcacy of chemotherapy and radiation therapy via normalization of
the tumor vasculature, thus improving the delivery of chemother-
apeutic drugs and oxygen (Kamoun et al., 2009; McGee et al., 2010).
Initial phase II studies in recurrent GBM (rGBM) patients demonstrated
promising results with signiﬁcant radiographic response rates and im-
proved progression-free survival (PFS) achieved with bevacizumab
therapy (Ferrara et al., 2004; Friedman et al., 2009; Kreisl et al., 2009;
Vredenburgh et al., 2007). On the basis of these results, the US Food
and Drug Administration granted approval for the use of bevacizumab
in rGBM in 2009. However, two subsequent randomized, placebo-
controlled phase III trials of bevacizumab with chemoradiotherapy in
patients with newly diagnosed GBM (nGBM) (NCT00884741 and
NCT00943826) failed to demonstrate an improvement in OS (Chinot
et al., 2014; Gilbert et al., 2014) (Table 1). Interestingly, these two
studies reported conﬂicting results regarding the quality of life and
cognitive function in the setting of bevacizumab treatment. Chinot et al.
reported maintenance of baseline quality of life and performance status
with bevacizumab treatment, and lower glucocorticoid requirement
(NCT00943826) (Chinot et al., 2014), while Gilbert et al. reported a
worse quality of life, and a decline in neurocognitive function in the
bevacizumab group (NCT00884741) (Gilbert et al., 2014). Diﬀerences
between these two studies may potentially come from variations in
recording neurocognitive function, as Trial #NCT00943826 evaluated
patient-reported health-related quality-of-life measures, while Trial #
NCT00884741 collected measures of symptom burden and interference
and the results of objective tests of neurocognitive function. The me-
chanisms of anti-VEGF treatment on neurological function in these
patients are less well studied. Previously, it has been shown that

329

N. Zhang et al.

Experimental Neurology 299 (2018) 326–333

Fig. 1. Anti-VEGF treatment leads to DRG ex-
plant degradation. Postnatal 1 to 2 day-old nude
mice pups were sacriﬁced and DRG were care-
fully dissected from the thoracic vertebrae down
to the lumbar vertebrae under microscope. After
removing the connective tissue and cut into thin
pieces, DRGs were explanted onto ammoniated
rat tail collagen- and poly-L-lysine-coated glass
cover slips and maintain in myelination medium
(Paivalainen et al., 2008). GFP-labeled schwan-
noma cells were seeded at the concentration of
5000 cells/well 5 days after DRG explantation.
One day later,
recombinant mouse VEGF
(100 ng/ml, R&D Systems, Minneapolis, MN) or
anti-VEGF antibody (B20, 100 μg/ml, Genentech,
South San Francisco, CA) were added into the
culture medium. DRGs without treatment were
used as control. DRG cultures in diﬀerent treat-
ment groups were imaged at 0 day (A–C) and
4 days after treatment by phase contrast micro-
scopy (4× objective, Olympus IX70 microscope).

bevacizumab treatment signiﬁcantly reduced brain edema, and the
reduction of edema is associated with a consistently stable quality of
life across all domains, sustained functional independence, and a di-
minished glucocorticoid requirement (Gerstner et al., 2009). These
studies suggest that a careful review of the eﬀect of bevacizumab on
brain edema and neurocognitive function would be needed to under-
stand these diﬀerences.

4. Eﬀect of anti-VEGF treatment on nerve function in patients with
NF2 vestibular schwannoma

Recent studies of anti-VEGF treatment in Neuroﬁbromatosis type 2
(NF2) schwannomas have shed light on the role of VEGF in the pro-
gression and nerve function and regeneration in tumors of the nervous
systems (Gao et al., 2015). NF2 is a dominantly inherited genetic
condition with a birth prevalence of 1 in 25,000 (Evans et al., 1992).
NF2 is characterized by bilateral vestibular schwannomas (VS), which
are benign tumors composed of neoplastic Schwann cells that arise from
the eighth cranial nerve that transmits hearing and balance information
from the ears to the brain. Although these VS grow slowly, they usually
lead to a signiﬁcant or total hearing loss by young adulthood or middle
age. The tumors can also compress the brain stem leading to headaches,
diﬃculty swallowing, and other serious neurologic symptoms (Plotkin
et al., 2014). Standard approaches for the treatment of growing VS
include surgical resection and radiation therapy (RT). While these tu-
mors can be successfully removed or destroyed with surgery and ra-
diation treatment, paradoxically, these therapeutic approaches can also
cause cranial nerve damage and associated adverse eﬀects, including
diminished hearing, swallow, and facial functions. For patients with
sporadic VS who do not have NF2, RT is associated with long-term
tumor control rates exceeding 95%. However, hearing preservation
rates after radiation range from 50 to 80% (Ammoun and Hanemann,
2011; Kano et al., 2009; Patel et al., 2014; Plotkin et al., 2012; Subach
et al., 1999; Timmer et al., 2011; Wagner et al., 2014). Post-RT out-
comes for patients with NF2 are inferior to those for sporadic patients,
with short-term local tumor control rates around 80–85% and hearing
preservation rates less than 50% (Ammoun and Hanemann, 2011).
Thus, the identiﬁcation of a novel adjunct therapy to enhance radio-
sensitivity while minimizing toxicity-related hearing loss in VS is ur-
gently needed.

Several previous investigations have suggested that – unlike other
benign tumors – VS, are able to induce the formation of new blood
vessels (di Tomaso et al., 2011; Plotkin et al., 2009), a characteristic
often associated with malignant
tumors. VEGF and its receptors
(VEGFRs) are expressed in VS, and VEGF expression level positively
correlates with schwannoma growth rate (Brieger et al., 2003; Caye-

Thomasen et al., 2003; Plotkin et al., 2009). Bevacizumab has been
associated with a reduction in the volume of most growing VS, and,
more importantly, improved hearing in 57% patients (Blakeley et al.,
2016; Plotkin et al., 2009). The fact that not all patients respond and
that hearing improvement is often transient, as well as the lack of direct
evidence of the eﬀects of anti-VEGF treatment on nerve function in-
dicate the need to better understand the mechanisms of anti-angiogenic
therapy on the function of tumor-bearing nerves.

5. Mechanisms of the neuroprotective eﬀect of anti-VEGF
treatment in NF2

In a sciatic nerve model of NF2, Gao et al., have shown that anti-
VEGF treatment improves neurological function. Under electron mi-
croscopy (EM), for the ﬁrst time, it has been reported that anti-VEGF
treatment leads to regeneration and remyelination of the nerve axons in
tumor-bearing mice (Gao et al., 2015). It has been further demonstrated
that the eﬀect of anti-VEGF treatment occurred via normalization of the
tumor vasculature and improvement in vessel perfusion (Gao et al.,
2015). This is consistent with previous ﬁndings that have shown im-
proved neural perfusion favors neuronal progenitor proliferation and
diﬀerentiation in vivo (Hoke, 2006; Lambrechts and Carmeliet, 2006;
Palmer et al., 2000; Webber and Zochodne, 2010). Furthermore, this
study reports that anti-VEGF treatment can signiﬁcantly alleviate
perineuronal edema, which faithfully recapitulates the clinical ﬁndings
in NF2 studies that patients with excess edema are most likely to beneﬁt
from bevacizumab treatment (Gao et al., 2015).

To study whether anti-VEGF treatment has a direct eﬀect on nerves,
organotypic culture models have been used (Fig. 1). Schwannoma cells
are co-cultured with dorsal root ganglia (DRG) explants, and treated
with control immunoglobulin, recombinant VEGF, or VEGF neutralizing
antibody (B20, Genentech). The results show that anti-VEGF antibody
treatment leads to signiﬁcant DRG and neurite degradation. These data
conﬁrm a direct role of VEGF on neuroprotection in the tumor model.
However, it raises the question: what is the dominant eﬀect of anti-
VEGF treatment in tumor models? In the NF2 schwannoma model, it
has been reported that anti-VEGF treatment does not signiﬁcantly de-
crease VEGF production (Gao et al., 2015); therefore, the direct neu-
roprotective eﬀect from VEGF remains unchanged. However, anti-VEGF
treatment signiﬁcantly normalizes tumor vasculature and improves
vessel perfusion. Therefore, the end result in this model is the dominant
vascular eﬀect that favors neuroprotection.

Anti-VEGF agents were originally developed to block tumor growth
by inhibiting blood vessel formation (Carmeliet and Jain, 2011; Goel
et al., 2011). However, bevacizumab has failed to improve survival
beneﬁt as a monotherapy in a number of tumors, but can confer

330

N. Zhang et al.

Experimental Neurology 299 (2018) 326–333

survival beneﬁt in combination with chemo- or immunotherapies (Goel
et al., 2011). Numerous preclinical and clinical studies have provided
evidence that the success of combined therapies stems from the fact that
bevacizumab “normalizes” the abnormal vasculature of tumors - the
resulting vasculature is structural and functionally more normal,
characterized by increased blood ﬂow and improved delivery of oxygen
(Goel et al., 2011). These studies suggest that in future clinical studies,
judicious use of anti-VEGF treatment is required to achieve vessel
normalization, and biomarker analysis of VEGF,
its receptors and
downstream signaling pathways should be considered to determine the
potential outcome of nerve preservation and neurological function.

6. Summary

Research in various diseases of the nervous system has shown that
VEGF has direct neuroprotective eﬀects in the central and peripheral
nervous system, as well as indirect eﬀects in improving neuronal vessel
perfusion which results in nerve protection. In tumors of the nervous
system, VEGF level is signiﬁcantly elevated and plays a critical role in
tumor angiogenesis and progression. The eﬀect of anti-VEGF treatment
on nerve protection and function is recently reported in NF2 schwan-
noma model- by normalizing the vasculature, anti-VEGF treatment is
able to relieve nerve edema and deliver oxygen more eﬃciently into the
nerve, and thus reduce nerve damage and improve nerve function. A
deeper understanding of the normalization process is required for anti-
VEGF treatment to be more eﬀectively exploited in restoring nerve
function in the clinical setting. Because of the dual role of VEGF on
nerve function, in future studies of both tumor and non-tumor asso-
ciated neurologic disease, the balance between the direct neuropro-
tective eﬀect and the indirect angiogenesis/vessel normalizing eﬀect
should be evaluated in each model.

Funding sources

This

study was

supported by Department of Defense New
Investigator Award, W81XWH-16-0219 (L.X.), American Cancer Society
Research Scholar Award, RSG-12-199 (L.X.), Children's Tumor
Foundation Drug Discovery Initiative (L.X.), Ira Spiro Award (L.X .),
P01-CA080124, P50-CA165962, R01-CA129371, R01-CA208205, and
U01-CA 224348 (R.K.J.), NCI Outstanding Investigator Award (R35-
CA197743), the Lustgarten Foundation, the Ludwig Center at Harvard,
the National Foundation for Cancer Research, and the Gates Foundation
(RKJ).

References

Acker, T., Beck, H., Plate, K.H., 2001. Cell type speciﬁc expression of vascular endothelial
growth factor and angiopoietin-1 and -2 suggests an important role of astrocytes in
cerebellar vascularization. Mech. Dev. 108, 45–57.

Al-Chalabi, A., van den Berg, L.H., Veldink, J., 2017. Gene discovery in amyotrophic

lateral sclerosis: implications for clinical management. Nat. Rev. Neurol. 13, 96–104.
Ammoun, S., Hanemann, C.O., 2011. Emerging therapeutic targets in schwannomas and

other merlin-deﬁcient tumors. Nat. Rev. Neurol. 7, 392–399.

Barouk, S., Hintz, T., Li, P., Duﬀy, A.M., MacLusky, N.J., Scharfman, H.E., 2011. 17Beta-
estradiol increases astrocytic vascular endothelial growth factor (VEGF) in adult fe-
male rat hippocampus. Endocrinology 152, 1745–1751.

von Baumgarten, L., Brucker, D., Tirniceru, A., Kienast, Y., Grau, S., Burgold, S., Herms,

J., Winkler, F., 2011. Bevacizumab has diﬀerential and dose-dependent eﬀects on
glioma blood vessels and tumor cells. Clin. Cancer Res. 17, 6192–6205.

Bengoetxea, H., Argandona, E.G., Lafuente, J.V., 2008. Eﬀects of visual experience on
vascular endothelial growth factor expression during the postnatal development of
the rat visual cortex. Cereb. Cortex 18, 1630–1639.

Blakeley, J.O., Ye, X., Duda, D.G., Halpin, C.F., Bergner, A.L., Muzikansky, A., Merker,
V.L., Gerstner, E.R., Fayad, L.M., Ahlawat, S., Jacobs, M.A., Jain, R.K., Zalewski, C.,
Dombi, E., Widemann, B.C., Plotkin, S.R., 2016. Eﬃcacy and biomarker study of
bevacizumab for hearing loss resulting from neuroﬁbromatosis type 2-associated
vestibular schwannomas. J. Clin. Oncol. 34, 1669–1675.

Bocker-Meﬀert, S., Rosenstiel, P., Rohl, C., Warneke, N., Held-Feindt, J., Sievers, J.,

Lucius, R., 2002. Erythropoietin and VEGF promote neural outgrowth from retinal
explants in postnatal rats. Invest. Ophthalmol. Vis. Sci. 43, 2021–2026.

Breier, G., Clauss, M., Risau, W., 1995. Coordinate expression of vascular endothelial

331

growth factor receptor-1 (ﬂt-1) and its ligand suggests a paracrine regulation of
murine vascular development. Dev. Dyn. 204, 228–239.

Brieger, J., Bedavanija, A., Lehr, H.A., Maurer, J., Mann, W.J., 2003. Expression of an-
giogenic growth factors in acoustic neurinoma. Acta Otolaryngol. 123, 1040–1045.
van Bruggen, N., Thibodeaux, H., Palmer, J.T., Lee, W.P., Fu, L., Cairns, B., Tumas, D.,

Gerlai, R., Williams, S.P., van Lookeren Campagne, M., Ferrara, N., 1999. VEGF
antagonism reduces edema formation and tissue damage after ischemia/reperfusion
injury in the mouse brain. J. Clin. Invest. 104, 1613–1620.

Calvo, C.F., Fontaine, R.H., Soueid, J., Tammela, T., Makinen, T., Alfaro-Cervello, C.,

Bonnaud, F., Miguez, A., Benhaim, L., Xu, Y., Barallobre, M.J., Moutkine, I., Lyytikka,
J., Tatlisumak, T., Pytowski, B., Zalc, B., Richardson, W., Kessaris, N., Garcia-
Verdugo, J.M., Alitalo, K., Eichmann, A., Thomas, J.L., 2011. Vascular endothelial
growth factor receptor 3 directly regulates murine neurogenesis. Genes Dev. 25,
831–844.

Carmeliet, P., 2003. Blood vessels and nerves: common signals, pathways and diseases.

Nat. Rev. Genet. 4, 710–720.

Carmeliet, P., Jain, R.K., 2000. Angiogenesis in cancer and other diseases. Nature 407,

249–257.

Carmeliet, P., Jain, R.K., 2011. Molecular mechanisms and clinical applications of an-

giogenesis. Nature 473, 298–307.

Caye-Thomasen, P., Baandrup, L., Jacobsen, G.K., Thomsen, J., Stangerup, S.E., 2003.
Immunohistochemical demonstration of vascular endothelial growth factor in ves-
tibular schwannomas correlates to tumor growth rate. Laryngoscope 113,
2129–2134.

Chinot, O.L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier,

A.F., Hoang-Xuan, K., Kavan, P., Cernea, D., Brandes, A.A., Hilton, M., Abrey, L.,
Cloughesy, T., 2014. Bevacizumab plus radiotherapy-temozolomide for newly diag-
nosed glioblastoma. N. Engl. J. Med. 370, 709–722.

Dvorak, H.F., Nagy, J.A., Feng, D., Brown, L.F., Dvorak, A.M., 1999. Vascular perme-

ability factor/vascular endothelial growth factor and the signiﬁcance of micro-
vascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237,
97–132.

Eppler, S.M., Combs, D.L., Henry, T.D., Lopez, J.J., Ellis, S.G., Yi, J.H., Annex, B.H.,
McCluskey, E.R., Zioncheck, T.F., 2002. A target-mediated model to describe the
pharmacokinetics and hemodynamic eﬀects of recombinant human vascular en-
dothelial growth factor in humans. Clin. Pharmacol. Ther. 72, 20–32.

Evans, D.G., Huson, S.M., Donnai, D., Neary, W., Blair, V., Newton, V., Harris, R., 1992. A

clinical study of type 2 neuroﬁbromatosis. Q. J. Med. 84, 603–618.

Falk, T., Yue, X., Zhang, S., McCourt, A.D., Yee, B.J., Gonzalez, R.T., Sherman, S.J., 2011.

Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of
Parkinson's disease. Neurosci. Lett. 496, 43–47.

Farkas, E., De Jong, G.I., Apro, E., De Vos, R.A., Steur, E.N., Luiten, P.G., 2000. Similar

ultrastructural breakdown of cerebrocortical capillaries in Alzheimer's disease,
Parkinson's disease, and experimental hypertension. What is the functional link? Ann.
N. Y. Acad. Sci. 903, 72–82.

Ferrara, N., 1999. Role of vascular endothelial growth factor in the regulation of angio-

genesis. Kidney Int. 56, 794–814.

Ferrara, N., Gerber, H.P., LeCouter, J., 2003. The biology of VEGF and its receptors. Nat.

Med. 9, 669–676.

Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W., 2004. Discovery and development of
bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3,
391–400.

Foxton, R.H., Finkelstein, A., Vijay, S., Dahlmann-Noor, A., Khaw, P.T., Morgan, J.E.,
Shima, D.T., Ng, Y.S., 2013. VEGF-A is necessary and suﬃcient for retinal neuro-
protection in models of experimental glaucoma. Am. J. Pathol. 182, 1379–1390.
Friedman, H.S., Prados, M.D., Wen, P.Y., Mikkelsen, T., Schiﬀ, D., Abrey, L.E., Yung,

W.K., Paleologos, N., Nicholas, M.K., Jensen, R., Vredenburgh, J., Huang, J., Zheng,
M., Cloughesy, T., 2009. Bevacizumab alone and in combination with irinotecan in
recurrent glioblastoma. J. Clin. Oncol. 27, 4733–4740.

Gao, X., Zhao, Y., Stemmer-Rachamimov, A.O., Liu, H., Huang, P., Chin, S., Selig, M.K.,

Plotkin, S.R., Jain, R.K., Xu, L., 2015. Anti-VEGF treatment improves neurological
function and augments radiation response in NF2 schwannoma model. Proc. Natl.
Acad. Sci. U. S. A. 112, 14676–14681.

Gerstner, E.R., Duda, D.G., di Tomaso, E., Ryg, P.A., Loeﬄer, J.S., Sorensen, A.G., Ivy, P.,
Jain, R.K., Batchelor, T.T., 2009. VEGF inhibitors in the treatment of cerebral edema
in patients with brain cancer. Nat. Rev. Clin. Oncol. 6, 229–236.

Gilbert, M.R., Dignam, J.J., Armstrong, T.S., Wefel, J.S., Blumenthal, D.T., Vogelbaum,
M.A., Colman, H., Chakravarti, A., Pugh, S., Won, M., Jeraj, R., Brown, P.D., Jaeckle,
K.A., Schiﬀ, D., Stieber, V.W., Brachman, D.G., Werner-Wasik, M., Tremont-Lukats,
I.W., Sulman, E.P., Aldape, K.D., Curran Jr., W.J., Mehta, M.P., 2014. A randomized
trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370,
699–708.

Goel, S., Duda, D.G., Xu, L., Munn, L.L., Boucher, Y., Fukumura, D., Jain, R.K., 2011.

Normalization of the vasculature for treatment of cancer and other diseases. Physiol.
Rev. 91, 1071–1121.

Grunstein, J., Roberts, W.G., Mathieu-Costello, O., Hanahan, D., Johnson, R.S., 1999.

Tumor-derived expression of vascular endothelial growth factor is a critical factor in
tumor expansion and vascular function. Cancer Res. 59, 1592–1598.

Guaiquil, V.H., Pan, Z., Karagianni, N., Fukuoka, S., Alegre, G., Rosenblatt, M.I., 2014.
VEGF-B selectively regenerates injured peripheral neurons and restores sensory and
trophic functions. Proc. Natl. Acad. Sci. U. S. A. 111, 17272–17277.

Hoke, A., 2006. Neuroprotection in the peripheral nervous system: rationale for more

eﬀective therapies. Arch. Neurol. 63, 1681–1685.

Jin, K.L., Mao, X.O., Greenberg, D.A., 2000. Vascular endothelial growth factor: direct

neuroprotective eﬀect in in vitro ischemia. Proc. Natl. Acad. Sci. U. S. A. 97,
10242–10247.

N. Zhang et al.

Experimental Neurology 299 (2018) 326–333

Jin, K., Mao, X.O., Batteur, S.P., McEachron, E., Leahy, A., Greenberg, D.A., 2001.

Caspase-3 and the regulation of hypoxic neuronal death by vascular endothelial
growth factor. Neuroscience 108, 351–358.

Jin, K., Zhu, Y., Sun, Y., Mao, X.O., Xie, L., Greenberg, D.A., 2002. Vascular endothelial
growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc. Natl. Acad.
Sci. U. S. A. 99, 11946–11950.

Kalaria, R.N., Cohen, D.L., Premkumar, D.R., Nag, S., LaManna, J.C., Lust, W.D., 1998.
Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral
ischemia. Brain Res. Mol. Brain Res. 62, 101–105.

Kamoun, W.S., Ley, C.D., Farrar, C.T., Duyverman, A.M., Lahdenranta, J., Lacorre, D.A.,
Batchelor, T.T., di Tomaso, E., Duda, D.G., Munn, L.L., Fukumura, D., Sorensen, A.G.,
Jain, R.K., 2009. Edema control by cediranib, a vascular endothelial growth factor
receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor
growth in mice. J. Clin. Oncol. 27, 2542–2552.

Kano, H., Kondziolka, D., Khan, A., Flickinger, J.C., Lunsford, L.D., 2009. Predictors of

hearing preservation after stereotactic radiosurgery for acoustic neuroma. J.
Neurosurg. 111, 863–873.

Kreisl, T.N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M.,
Butman, J.A., Camphausen, K., Park, J., Albert, P.S., Fine, H.A., 2009. Phase II trial of
single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor pro-
gression in recurrent glioblastoma. J. Clin. Oncol. 27, 740–745.

Lambrechts, D., Carmeliet, P., 2006. VEGF at the neurovascular interface: therapeutic
implications for motor neuron disease. Biochim. Biophys. Acta 1762, 1109–1121.

Lambrechts, D., Storkebaum, E., Morimoto, M., Del-Favero, J., Desmet, F., Marklund, S.L.,
Wyns, S., Thijs, V., Andersson, J., van Marion, I., Al-Chalabi, A., Bornes, S., Musson,
R., Hansen, V., Beckman, L., Adolfsson, R., Pall, H.S., Prats, H., Vermeire, S.,
Rutgeerts, P., Katayama, S., Awata, T., Leigh, N., Lang-Lazdunski, L., Dewerchin, M.,
Shaw, C., Moons, L., Vlietinck, R., Morrison, K.E., Robberecht, W., Van Broeckhoven,
C., Collen, D., Andersen, P.M., Carmeliet, P., 2003. VEGF is a modiﬁer of amyotrophic
lateral sclerosis in mice and humans and protects motoneurons against ischemic
death. Nat. Genet. 34, 383–394.

Le Bras, B., Barallobre, M.J., Homman-Ludiye, J., Ny, A., Wyns, S., Tammela, T., Haiko,
P., Karkkainen, M.J., Yuan, L., Muriel, M.P., Chatzopoulou, E., Breant, C., Zalc, B.,
Carmeliet, P., Alitalo, K., Eichmann, A., Thomas, J.L., 2006. VEGF-C is a trophic
factor for neural progenitors in the vertebrate embryonic brain. Nat. Neurosci. 9,
340–348.

Lee, J., Kim, E., Ryu, S.W., Choi, C., Choi, K., 2016. Combined inhibition of vascular

endothelial growth factor receptor signaling with temozolomide enhances cytotoxi-
city against human glioblastoma cells via downregulation of Neuropilin-1. J. Neuro-
Oncol. 128, 29–34.

Lennmyr, F., Ata, K.A., Funa, K., Olsson, Y., Terent, A., 1998. Expression of vascular

endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) following per-
manent and transient occlusion of the middle cerebral artery in the rat. J.
Neuropathol. Exp. Neurol. 57, 874–882.

Li, S.F., Sun, Y.B., Meng, Q.H., Li, S.R., Yao, W.C., Hu, G.J., Li, Z.J., Wang, R.Z., 2009.
Recombinant adeno-associated virus serotype 1-vascular endothelial growth factor
promotes neurogenesis and neuromigration in the subventricular zone and rescues
neuronal function in ischemic rats. Neurosurgery 65, 771–779 (discussion 779).

Li, Z., Burns, A.R., Han, L., Rumbaut, R.E., Smith, C.W., 2011. IL-17 and VEGF are ne-

cessary for eﬃcient corneal nerve regeneration. Am. J. Pathol. 178, 1106–1116.

Licht, T., Eavri, R., Goshen, I., Shlomai, Y., Mizrahi, A., Keshet, E., 2010. VEGF is required

for dendritogenesis of newly born olfactory bulb interneurons. Development 137,
261–271.

Licht, T., Goshen, I., Avital, A., Kreisel, T., Zubedat, S., Eavri, R., Segal, M., Yirmiya, R.,
Keshet, E., 2011. Reversible modulations of neuronal plasticity by VEGF. Proc. Natl.
Acad. Sci. U. S. A. 108, 5081–5086.

Lin, C.S., Lue, T.F., 2004. Growth factor therapy and neuronal nitric oxide synthase. Int. J.

Impot. Res. 16 (Suppl. 1), S38–39.

Lin, G., Chen, K.C., Hsieh, P.S., Yeh, C.H., Lue, T.F., Lin, C.S., 2003. Neurotrophic eﬀects

of vascular endothelial growth factor and neurotrophins on cultured major pelvic
ganglia. BJU Int. 92, 631–635.

Louissaint Jr., A., Rao, S., Leventhal, C., Goldman, S.A., 2002. Coordinated interaction of

neurogenesis and angiogenesis in the adult songbird brain. Neuron 34, 945–960.
Lu-Emerson, C., Duda, D.G., Emblem, K.E., Taylor, J.W., Gerstner, E.R., Loeﬄer, J.S.,

Batchelor, T.T., Jain, R.K., 2015. Lessons from anti-vascular endothelial growth
factor and anti-vascular endothelial growth factor receptor trials in patients with
glioblastoma. J. Clin. Oncol. 33, 1197–1213.

Maharaj, A.S., Saint-Geniez, M., Maldonado, A.E., D'Amore, P.A., 2006. Vascular en-

dothelial growth factor localization in the adult. Am. J. Pathol. 168, 639–648.

McGee, M.C., Hamner, J.B., Williams, R.F., Rosati, S.F., Sims, T.L., Ng, C.Y., Gaber, M.W.,
Calabrese, C., Wu, J., Nathwani, A.C., Duntsch, C., Merchant, T.E., Davidoﬀ, A.M.,
2010. Improved intratumoral oxygenation through vascular normalization increases
glioma sensitivity to ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 76,
1537–1545.

Mohammadi, R., Ahsan, S., Masoumi, M., Amini, K., 2013. Vascular endothelial growth
factor promotes peripheral nerve regeneration after sciatic nerve transection in rat.
Chin. J. Traumatol. 16, 323–329.

Nishijima, K., Ng, Y.S., Zhong, L., Bradley, J., Schubert, W., Jo, N., Akita, J., Samuelsson,
S.J., Robinson, G.S., Adamis, A.P., Shima, D.T., 2007. Vascular endothelial growth
factor-A is a survival factor for retinal neurons and a critical neuroprotectant during
the adaptive response to ischemic injury. Am. J. Pathol. 171, 53–67.

Oku, T., Tjuvajev, J.G., Miyagawa, T., Sasajima, T., Joshi, A., Joshi, R., Finn, R., Claﬀey,
K.P., Blasberg, R.G., 1998. Tumor growth modulation by sense and antisense vascular
endothelial growth factor gene expression: eﬀects on angiogenesis, vascular perme-
ability, blood volume, blood ﬂow, ﬂuorodeoxyglucose uptake, and proliferation of
human melanoma intracerebral xenografts. Cancer Res. 58, 4185–4192.

Oosthuyse, B., Moons, L., Storkebaum, E., Beck, H., Nuyens, D., Brusselmans, K., Van
Dorpe, J., Hellings, P., Gorselink, M., Heymans, S., Theilmeier, G., Dewerchin, M.,
Laudenbach, V., Vermylen, P., Raat, H., Acker, T., Vleminckx, V., Van Den Bosch, L.,
Cashman, N., Fujisawa, H., Drost, M.R., Sciot, R., Bruyninckx, F., Hicklin, D.J., Ince,
C., Gressens, P., Lupu, F., Plate, K.H., Robberecht, W., Herbert, J.M., Collen, D.,
Carmeliet, P., 2001. Deletion of the hypoxia-response element in the vascular en-
dothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28,
131–138.

Paivalainen, S., Nissinen, M., Honkanen, H., Lahti, O., Kangas, S.M., Peltonen, J.,

Peltonen, S., Heape, A.M., 2008. Myelination in mouse dorsal root ganglion/Schwann
cell cocultures. Mol. Cell. Neurosci. 37, 568–578.

Palmer, T.D., Willhoite, A.R., Gage, F.H., 2000. Vascular niche for adult hippocampal

neurogenesis. J. Comp. Neurol. 425, 479–494.

Pan, Z., Fukuoka, S., Karagianni, N., Guaiquil, V.H., Rosenblatt, M.I., 2013. Vascular

endothelial growth factor promotes anatomical and functional recovery of injured
peripheral nerves in the avascular cornea. FASEB J. 27, 2756–2767.

Patel, J., Vasan, R., van Loveren, H., Downes, K., Agazzi, S., 2014. The changing face of

acoustic neuroma management in the USA: analysis of the 1998 and 2008 patient
surveys from the acoustic neuroma association. Br. J. Neurosurg. 28, 20–24.

Pereira Lopes, F.R., Lisboa, B.C., Frattini, F., Almeida, F.M., Tomaz, M.A., Matsumoto,

P.K., Langone, F., Lora, S., Melo, P.A., Borojevic, R., Han, S.W., Martinez, A.M., 2011.
Enhancement of sciatic nerve regeneration after vascular endothelial growth factor
(VEGF) gene therapy. Neuropathol. Appl. Neurobiol. 37, 600–612.

Plate, K.H., Beck, H., Danner, S., Allegrini, P.R., Wiessner, C., 1999. Cell type speciﬁc
upregulation of vascular endothelial growth factor in an MCA-occlusion model of
cerebral infarct. J. Neuropathol. Exp. Neurol. 58, 654–666.

Plotkin, S.R., Stemmer-Rachamimov, A.O., Barker 2nd, F.G., Halpin, C., Padera, T.P.,
Tyrrell, A., Sorensen, A.G., Jain, R.K., di Tomaso, E., 2009. Hearing improvement
after bevacizumab in patients with neuroﬁbromatosis type 2. N. Engl. J. Med. 361,
358–367.

Plotkin, S.R., Merker, V.L., Halpin, C., Jennings, D., McKenna, M.J., Harris, G.J., Barker

2nd, F.G., 2012. Bevacizumab for progressive vestibular schwannoma in neuroﬁ-
bromatosis type 2: a retrospective review of 31 patients. Otol. Neurotol. 33,
1046–1052.

Plotkin, S.R., Merker, V.L., Muzikansky, A., Barker 2nd, F.G., Slattery 3rd, W., 2014.

Natural history of vestibular schwannoma growth and hearing decline in newly di-
agnosed neuroﬁbromatosis type 2 patients. Otol. Neurotol. 35, e50–56.

Raab, S., Plate, K.H., 2007. Diﬀerent networks, common growth factors: shared growth
factors and receptors of the vascular and the nervous system. Acta Neuropathol. 113,
607–626.

Ruiz de Almodovar, C., Lambrechts, D., Mazzone, M., Carmeliet, P., 2009. Role and
therapeutic potential of VEGF in the nervous system. Physiol. Rev. 89, 607–648.

Ruiz de Almodovar, C., Coulon, C., Salin, P.A., Knevels, E., Chounlamountri, N., Poesen,
K., Hermans, K., Lambrechts, D., Van Geyte, K., Dhondt, J., Dresselaers, T., Renaud,
J., Aragones, J., Zacchigna, S., Geudens, I., Gall, D., Stroobants, S., Mutin, M.,
Dassonville, K., Storkebaum, E., Jordan, B.F., Eriksson, U., Moons, L., D'Hooge, R.,
Haigh, J.J., Belin, M.F., Schiﬀmann, S., Van Hecke, P., Gallez, B., Vinckier, S.,
Chedotal, A., Honnorat, J., Thomasset, N., Carmeliet, P., Meissirel, C., 2010. Matrix-
binding vascular endothelial growth factor (VEGF) isoforms guide granule cell mi-
gration in the cerebellum via VEGF receptor Flk1. J. Neurosci. 30, 15052–15066.

Schanzer, A., Wachs, F.P., Wilhelm, D., Acker, T., Cooper-Kuhn, C., Beck, H., Winkler, J.,
Aigner, L., Plate, K.H., Kuhn, H.G., 2004. Direct stimulation of adult neural stem cells
in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol.
14, 237–248.

Schratzberger, P., Schratzberger, G., Silver, M., Curry, C., Kearney, M., Magner, M., Alroy,
J., Adelman, L.S., Weinberg, D.H., Ropper, A.H., Isner, J.M., 2000. Favorable eﬀect of
VEGF gene transfer on ischemic peripheral neuropathy. Nat. Med. 6, 405–413.

Shvartsman, D., Storrie-White, H., Lee, K., Kearney, C., Brudno, Y., Ho, N., Cezar, C.,

McCann, C., Anderson, E., Koullias, J., Tapia, J.C., Vandenburgh, H., Lichtman, J.W.,
Mooney, D.J., 2014. Sustained delivery of VEGF maintains innervation and promotes
reperfusion in ischemic skeletal muscles via NGF/GDNF signaling. Mol. Ther. 22,
1243–1253.

Simon-Yarza, T., Formiga, F.R., Tamayo, E., Pelacho, B., Prosper, F., Blanco-Prieto, M.J.,
2013. PEGylated-PLGA microparticles containing VEGF for long term drug delivery.
Int. J. Pharm. 440, 13–18.

Son, M.J., Kim, J.S., Kim, M.H., Song, H.S., Kim, J.T., Kim, H., Shin, T., Jeon, H.J., Lee,
D.S., Park, S.Y., Kim, Y.J., Kim, J.H., Nam, D.H., 2006. Combination treatment with
temozolomide and thalidomide inhibits tumor growth and angiogenesis in an or-
thotopic glioma model. Int. J. Oncol. 28, 53–59.

Sondell, M., Lundborg, G., Kanje, M., 1999. Vascular endothelial growth factor has

neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and
Schwann cell proliferation in the peripheral nervous system. J. Neurosci. 19,
5731–5740.

Subach, B.R., Kondziolka, D., Lunsford, L.D., Bissonette, D.J., Flickinger, J.C., Maitz, A.H.,
1999. Stereotactic radiosurgery in the management of acoustic neuromas associated
with neuroﬁbromatosis Type 2. J. Neurosurg. 90, 815–822.

Sun, Y., Jin, K., Xie, L., Childs, J., Mao, X.O., Logvinova, A., Greenberg, D.A., 2003. VEGF-

induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral
ischemia. J. Clin. Invest. 111, 1843–1851.

Sun, Y., Jin, K., Childs, J.T., Xie, L., Mao, X.O., Greenberg, D.A., 2006. Vascular en-

dothelial growth factor-B (VEGFB) stimulates neurogenesis: evidence from knockout
mice and growth factor administration. Dev. Biol. 289, 329–335.

Timmer, F.C., Mulder, J.J., Hanssens, P.E., van Overbeeke, J.J., Donders, R.T., Cremers,
C.W., Graamans, K., 2011. Gamma knife radiosurgery for vestibular schwannomas:
identiﬁcation of predictors for continued tumor growth and the inﬂuence of docu-
mented tumor growth preceding radiation treatment. Laryngoscope 121, 1834–1838.

332

N. Zhang et al.

Experimental Neurology 299 (2018) 326–333

di Tomaso, E., Snuderl, M., Kamoun, W.S., Duda, D.G., Auluck, P.K., Fazlollahi, L.,

Andronesi, O.C., Frosch, M.P., Wen, P.Y., Plotkin, S.R., Hedley-Whyte, E.T., Sorensen,
A.G., Batchelor, T.T., Jain, R.K., 2011. Glioblastoma recurrence after cediranib
therapy in patients: lack of “rebound” revascularization as mode of escape. Cancer
Res. 71, 19–28.

de la Torre, J.C., 2000. Cerebral hypoperfusion, capillary degeneration, and development

of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 14 (Suppl. 1), S72–81.

Tsuzuki, Y., Fukumura, D., Oosthuyse, B., Koike, C., Carmeliet, P., Jain, R.K., 2000.
Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-in-
ducible factor-1alpha → hypoxia response element → VEGF cascade diﬀerentially
regulates vascular response and growth rate in tumors. Cancer Res. 60, 6248–6252.

Van Den Bosch, L., Storkebaum, E., Vleminckx, V., Moons, L., Vanopdenbosch, L.,

Scheveneels, W., Carmeliet, P., Robberecht, W., 2004. Eﬀects of vascular endothelial
growth factor (VEGF) on motor neuron degeneration. Neurobiol. Dis. 17, 21–28.

Verhoeﬀ, J.J., Stalpers, L.J., Claes, A., Hovinga, K.E., Musters, G.D., Peter Vandertop, W.,
Richel, D.J., Leenders, W.P., van Furth, W.R., 2009. Tumour control by whole brain
irradiation of anti-VEGF-treated mice bearing intracerebral glioma. Eur. J. Cancer 45,
3074–3080.

Vredenburgh, J.J., Desjardins, A., Herndon 2nd, J.E., Marcello, J., Reardon, D.A., Quinn,
J.A., Rich, J.N., Sathornsumetee, S., Gururangan, S., Sampson, J., Wagner, M., Bailey,
L., Bigner, D.D., Friedman, A.H., Friedman, H.S., 2007. Bevacizumab plus irinotecan
in recurrent glioblastoma multiforme. J. Clin. Oncol. 25, 4722–4729.

Wagner, J., Welzel, T., Habermehl, D., Debus, J., Combs, S.E., 2014. Radiotherapy in

patients with vestibular schwannoma and neuroﬁbromatosis type 2: clinical results
and review of the literature. Tumori 100, 189–194.

Webber, C., Zochodne, D., 2010. The nerve regenerative microenvironment: early be-

havior and partnership of axons and Schwann cells. Exp. Neurol. 223, 51–59.

Winkler, F., Kozin, S.V., Tong, R.T., Chae, S.S., Booth, M.F., Garkavtsev, I., Xu, L., Hicklin,
D.J., Fukumura, D., di Tomaso, E., Munn, L.L., Jain, R.K., 2004. Kinetics of vascular
normalization by VEGFR2 blockade governs brain tumor response to radiation: role
of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6,
553–563.

Wittko, I.M., Schanzer, A., Kuzmichev, A., Schneider, F.T., Shibuya, M., Raab, S., Plate,
K.H., 2009. VEGFR-1 regulates adult olfactory bulb neurogenesis and migration of
neural progenitors in the rostral migratory stream in vivo. J. Neurosci. 29,
8704–8714.

Xu, L., Fukumura, D., Jain, R.K., 2002. Acidic extracellular pH induces vascular en-

dothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK sig-
naling pathway: mechanism of low pH-induced VEGF. J. Biol. Chem. 277,
11368–11374.

Yu, C.Q., Zhang, M., Matis, K.I., Kim, C., Rosenblatt, M.I., 2008. Vascular endothelial

growth factor mediates corneal nerve repair. Invest. Ophthalmol. Vis. Sci. 49,
3870–3878.

Yuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., Jain, R.K., 1996. Time-de-
pendent vascular regression and permeability changes in established human tumor
xenografts induced by an anti-vascular endothelial growth factor/vascular perme-
ability factor antibody. Proc. Natl. Acad. Sci. U. S. A. 93, 14765–14770.

Zhang, Z.G., Zhang, L., Jiang, Q., Zhang, R., Davies, K., Powers, C., Bruggen, N., Chopp,
M., 2000. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in
the ischemic brain. J. Clin. Invest. 106, 829–838.

333

